Department of Pharmacology, Hassan Institute of Medical Sciences, Hassan, India.
Indian J Pharmacol. 2011 Apr;43(2):176-9. doi: 10.4103/0253-7613.77357.
The purpose of this study has been to assess the efficacy of duloxetine, a selective inhibitor of serotonin and norepinephrine reuptake, in the treatment of stress urinary incontinence (SUI) in women.
The study included 50 women aged above 18 years with a predominant symptom of stress urinary incontinence (SUI). The case definition included a predominant symptom of SUI with a weekly incontinence episode frequency (IEF) of seven or greater and a positive cough stress test. All the patients received duloxetine 20 mg twice daily for 12 weeks. The primary outcome variables included the IEF and improvement in quality of life. Paired Student's 't' test was used to analyze changes in IEF.
The improvement with duloxetine treatment was found in 40 out of 50 patients. Remaining 10 patients did not show any improvement with duloxetine and discontinued the treatment. In 40 patients, the mean baseline IEF was 12.5/week. At the end of three months treatment, IEF was six/week. This shows a statistically significant reduction in the IEF. Also, there was a good improvement in quality of life with 65% of patients in the "very much better" and "much better" categories according to PGI-I scale. In the remaining 10 patients, there was no significant improvement after one month of treatment and patients underwent surgery.
The findings support duloxetine as a potential treatment for women with stress urinary incontinence.
本研究旨在评估度洛西汀（一种选择性 5-羟色胺和去甲肾上腺素再摄取抑制剂）治疗女性压力性尿失禁（SUI）的疗效。
该研究纳入了 50 名年龄在 18 岁以上、以压力性尿失禁（SUI）为主诉的女性。病例定义包括以 SUI 为主诉，每周失禁发作频率（IEF）为 7 次或更多，咳嗽应激试验阳性。所有患者均接受度洛西汀 20mg，每日两次，治疗 12 周。主要结局变量包括 IEF 和生活质量改善。采用配对学生 t 检验分析 IEF 的变化。
在 50 名患者中，有 40 名患者接受度洛西汀治疗后症状得到改善。其余 10 名患者未接受度洛西汀治疗，且症状无改善而停药。在 40 名患者中，基线 IEF 平均为 12.5/周。治疗 3 个月后，IEF 为 6/周。这表明 IEF 显著减少。同时，根据 PGI-I 量表，65%的患者生活质量得到了很好的改善，处于“非常好”和“好”的类别。在其余 10 名患者中，治疗 1 个月后无明显改善，患者接受了手术。
这些发现支持度洛西汀作为治疗女性压力性尿失禁的一种潜在方法。
